


**ABRAHAM NYSKA, DVM, Dipl. ECVP, Fellow IATP,**  
**Diplomate, European College of Veterinary pathology (Dipl. ECVP),**  
**Fellow, International Academy of Toxicologic Pathology**  
**Expert in Toxicologic Pathology**  
**Visiting Full Professor of Pathology, Sackler School of Medicine, Tel Aviv University**  
**Yehuda HaMaccabi 31, Tel Aviv, 6200515, Israel**  
**CELL: 054 3003447**  
**EMAIL: [anyska@nyska.net](mailto:anyska@nyska.net)**  
**Website: <http://www.nyska.net>**



#### **SUMMARY OF BIOGRAPHY AND EXPERTISE:**

- Prof. Abraham Nyska is an **expert in toxicologic pathology**, holding two diplomas and formal recognition in **toxicologic pathology**, reflecting a formal recognition by international professional organizations, desired by regulatory agencies (such as the **FDA** and **EMA**)

#### **1. Diplomate of the European College of Veterinary Pathologist (Board ECVP)**

website <https://www.ecvpath.org/user/9640/profil>

#### **Information about the “European College of Veterinary Pathologists”**

**The Board ECVP is equivalent to the Board ACVP, and are mutually recognized by international regulatory agencies such as the FDA.**

**The Board ECVP qualification is accepted on equal terms by the well-established American College of Veterinary Pathologists (ACVP).**

2007;34(4):473-7. <https://pubmed.ncbi.nlm.nih.gov/18287475/>

**The certification is presented in the Appendix A, below.**

#### **2. Fellow of the International Academy of Toxicologic Pathology (IATP)**

<http://iatpfellow.org/index.php>

#### **Information about the “International Academy of Toxicologic Pathology”**

The International Academy of Toxicologic Pathology (IATP) is a global professional scientific organization that establishes the criteria of excellence and accomplishments in


toxicologic pathology for accreditation of members (fellows), serves as a worldwide source of experts in toxicologic pathology and organizes unique educational opportunities for toxicologic pathologists, related scientists, and trainees.

- Prof. Abraham Nyska, is a **Visiting Full Professor of Pathology, Faculty of Exact Sciences, Tel Aviv University** (see certificate as flows)
- Prof. Nyska has more than 46 years' experience in **consultation, evaluation, and pre-clinical risk assessment**, dealing with toxicologic pathology aspects of **chemicals, drugs, medical devices, and stem cells. These consultations are pivotal, contributing to the commercial success of the start-up/ and or, pharma companies.**
- He worked for 10 years as a staff scientist and expert in Toxicologic Pathology at the American National Toxicology Program (NTP) of the National Institute of Health (NIH), followed by 8 year as an NTP Consultant.
- Prof. Nyska serves as an Associate Editor and Senior Consultant of "Toxicologic Pathology". He has strong research-oriented attitude and vast collaboration with top federal research institutes (i.e., NIH, EPA) and academic institutes, with more than **497 publications** in peer-reviewed journals. Prof. Nyska is a consultant in Toxicologic Pathology to pharmaceutical companies, CRO's, and Federal institutes in Israel, Europe, India and the USA.
- His considerable deep knowledge, long-standing expertise, and dedication in the area of Toxicologic Pathology has earned him twice the highly valued NIH Director Award "In recognition of consistent dedication and teamwork, insuring quality evaluation and interpretation of pathology aspects of NTP studies", and "For highly significant scientific and technical contributions to the analysis and reporting of the NTP "dioxin-like chemicals" initiative".

- Some **recent examples of FDA's clearance** in which prof. Nyska did the **toxicologic pathology evaluation**, are as follows:

- **BioProtect** secures FDA approval for biodegradable balloon  
Using a blunted tip insertion device, the biodegradable spacer can be deployed through a rapid and minimally invasive procedure.

<https://www.medicaldevice-network.com/news/bioprotect-fda-approval-biodegradable-balloon/?cf-view>



The new generation spacer helps provide optimal protection to the rectum during prostate cancer radiation therapy. Credit: MattL\_Images / Shutterstock.com.

- **Nurami** receives US FDA approval for resorbable repair graft  
ArtiFascia integrates two layers of electrospun nanofibres to create biomimetic scaffolds and a non-porous barrier layer.


<https://www.medicaldevice-network.com/news/nurami-fda-approval-resorbable-repair-graft/>



Neurosurgeries involve the replacement of the Dura Mater, a protective layer for the brain and cerebrospinal fluid. Credit: sfam\_photo / Shutterstock.com.

- **Belkin Vision** Announces FDA Clearance for Its Eagle Device

<https://www.visionmonday.com/business/article/belkin-vision-announces-fda-clearance-for-its-eagle-device/>




- **FDA approves Stryker's biodegradable subacromial balloon spacer**

<https://www.medicaldevice-network.com/news/fda-stryker-subacromial-balloon/>



- \* **Venus Concept** Receives 510(k) Clearance for Use of its ALME™ Next Generation Robotic Technology for Fractional Skin Resurfacing

<https://ir.venusconcept.com/news-releases/news-release-details/venus-concept-receives-510k-clearance-use-its-aimetm-next>



- Some **examples** of these commercial successes in which prof. Nyska did the toxicologic pathology evaluation, are as follows:
  - **Alcon buys Israeli glaucoma** treatment co Optonol  
<https://en.globes.co.il/en/article-1000522484>
  - **Mitsubishi Tanabe buys up NeuroDerm**  
<https://www.fiercebiotech.com/biotech/mitsubishi-tanabe-buys-up-neuroderm-1-1b-deal>
  - \$1b SPAC deal seen for Israeli medical robotics co Memic  
<https://en.globes.co.il/en/article-1b-spac-deal-seen-for-israeli-medical-robotics-co-memic-1001371702>
  - **Bard buys Israeli hernia mesh co LifeBond**  
<https://en.globes.co.il/en/article-bard-buys-israeli-hernia-mesh-co-lifebond-1001314875>
  - The phase I/II clinical study of the **first european DNA vaccine against COVID-19** has started in Italy  
<https://www.rottapharmbiotech.com/01-march-2021-press-release/>
  - **NRx and Israel partner** to advance Covid-19 vaccine development  
<https://www.pharmaceutical-technology.com/news/nrx-israel-vaccine-development/>
  - **Stryker buys Israeli orthopedic device co OrthoSpace** for \$220m  
<https://en.globes.co.il/en/article-stryker-buys-israeli-orthopedic-device-co-orthospace-for-220m-1001278114>
  - **Teva and MedinCell** Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia  
<https://www.tevapharm.com/news-and-media/latest-news/teva-and-medincell-announce-fda-acceptance-of-new-drug-application-for-tv-46000mdc-irm-as-a-treatment-fo/>
- Prof. Nyska worked for 10 years as a senior staff scientist and expert in Toxicologic Pathology at the **American National Toxicology Program (NTP)** of the National

Institute of Health (NIH), followed by 8 year as an NTP Consultant. **Examples of awards related to his work at the NTP are presented in Appendix A.**

- Prof. Nyska served for 15 years as an Associate Editor of “Toxicologic Pathology”, and now serves as a senior adviser to this journal. He has strong research-oriented attitude and vast collaboration with top federal research institutes (i.e., NIH, EPA) and academic institutes, with more than **500 publications** in peer-reviewed journals (**see link for publications as follows: <https://www.researchgate.net/profile/Abraham-Nyska>**), **and few examples of titles from recent publications, included in Appendix B. Prof. Nyska is a consultant in Toxicologic Pathology to pharmaceutical companies, CRO’s, and Federal institutes in Israel, Europe, India and the USA.**
- His considerable deep knowledge, long-standing expertise, and dedication in the area of Toxicologic Pathology has earned him twice the highly valued NIH Director Award *“In recognition of consistent dedication and teamwork, insuring quality evaluation and interpretation of pathology aspects of NTP studies”*, and *“For highly significant scientific and technical contributions to the analysis and reporting of the NTP “dioxin-like chemicals” initiative”*.

#### **APPENDIX A:**

**Diploma, European College Veterinary Pathologist (Diplomate ECVP)**

**EBVS** EUROPEAN BOARD  
OF VETERINARY  
SPECIALISATION

THIS IS TO CERTIFY THAT


Prof. Abraham Nyska

has met the standards to be awarded the title  
EBVS<sup>®</sup> European Specialist in Veterinary Pathology

for the period: 2023 - 2028



Dr Alexandre BIDAUT  
President ECVF



Prof Zoe Polizopoulou  
President EBVS



Validation Code: 5qggi6rx

**Examples of National Institute of Health (NIH) awards:**




National Institutes of Health  
Award of Merit

*presented to*

Abraham Nyska, D.V.M.

For highly significant scientific and  
technical contributions to the analysis and reporting  
of the NTP 'dioxin-like chemicals' initiative.

Presented December 14, 2004

  
Director, NIEHS





*National Institutes of Health  
NIH Director's Award*

*is presented to*

*Abraham Nyska, D.V.M.*

*In recognition of consistent dedication and teamwork  
insuring quality evaluation and interpretation of  
pathology aspects of NTP studies.*

*June 22, 2000*

*Ruth L. Kirschstein*  
*Acting Director, NIH*

## Visiting Full Professor of Pathology, Faculty of Exact Sciences, Tel Aviv University

●●● Porter School of  
the Environment and  
Earth Sciences  
**Environmental Studies Dep.**



The Raymond and Beverly Sackler  
Faculty of Exact Sciences  
Tel Aviv University

הפקולטה למדעים מדויקים  
ע"ש ריימונד ובברלי סאקלר  
אוניברסיטת תל אביב

●●● בית הספר לסביבה  
ולמדעי כדור הארץ  
על שם פורטר

**החוג ללימודי הסביבה**

20/08/2023  
05069764-8 .ת.ז.

לכבוד  
פרופ' אברהם ניסקה  
בית הספר לסביבה ולמדעי כדור הארץ  
כאן

שלום רב,

הרינו להודיעך כי רשויות האוניברסיטה החליטו להזמין כמתנדב ביחידה: בית הספר לסביבה  
ולמדעי כדור הארץ מיום 01-10-2023 עד יום 30-09-2024

מינוי זה אינו נושא עמו תמורה כספית.

תנאי עבודתך בהתאם לתקנון מינויים של מורים אורחים (תשמ"ה) ובהתאם להוראות נהל  
העסקת מתנדבים באוניברסיטה [הוראה 008 - 04] ובכפוף לחתימתך על טופס ההתנדבות.

הרינו מברכים אותך ומודים לך על התנדבותך לאוניברסיטה.

בכבוד רב,

פרופ' טובה מיליא  
דקאנית הפקולטה למדעים מדויקים

## APPENDIX B: Examples of titles of recent publications:

Scientific and Regulatory Policy Committee

This Points to Consider article is a product of a Society of Toxicologic Pathology (STP) Working Group commissioned by the Scientific and Regulatory Policy Committee (SRPC) of the STP. It has been reviewed and approved by the SRPC and Executive Committee of the STP but does not represent a formal best practice recommendation of the Society; rather, it is intended to provide key "points to consider" in designing studies or interpreting data from toxicity and safety studies intended to support regulatory submissions. The views expressed in this article are those of the authors and do not represent the policies, positions, or opinions of their respective agencies and organizations. Readers of *Toxicologic Pathology* are encouraged to send their thoughts on these articles or ideas for new topics to the Editor.

Toxicologic Pathology  
2022, Vol. 50(4) 512–530  
© The Author(s) 2022  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/01926233221103202  
journals.sagepub.com/home/tpx  
SAGE

### Scientific and Regulatory Policy Committee Points to Consider for Medical Device Implant Site Evaluation in Nonclinical Studies

Maureen T. O'Brien<sup>1</sup>, JoAnn C. L. Schuh<sup>2</sup>, Lyn M. Wancket<sup>3</sup>,  
Sarah D. Cramer<sup>4</sup>, Kathleen A. Funk<sup>5</sup>, Nicolette D. Jackson<sup>6</sup>,  
Kamala Kannan<sup>7</sup>, Kevin Keane<sup>8</sup>, Abraham Nyska<sup>9</sup>,  
Serge D. Roussele<sup>4</sup>, Adrienne Schucker<sup>1</sup>, Valerie S. Thomas<sup>10</sup>,  
and Stefan Tunev<sup>11</sup>

#### Abstract

Nonclinical implantation studies are a common and often critical step for medical device safety assessment in the bench-to-market pathway. Nonclinical implanted medical devices or drug-device combination products require complex macroscopic and microscopic pathology evaluations due to the physical presence of the device itself and unique tissue responses to device materials. The Medical Device Implant Site Evaluation working group of the Society of Toxicologic Pathology's (STP) Scientific and Regulatory Policy Committee (SRPC) was tasked with reviewing scientific, technical, and regulatory considerations for these studies. Implant site evaluations require highly specialized methods and analytical schemes that should be designed on a case-by-case basis to address specific study objectives. Existing STP best practice recommendations can serve as a framework when performing nonclinical studies under Good Laboratory Practices and help mitigate limitations in standards and guidances for implant evaluations (e.g., those from the International Organization for Standardization [ISO], ASTM International). This article integrates standards referenced by sponsors and regulatory bodies with practical pathology evaluation methods for implantable medical devices and combination products. The goal is to ensure the maximum accuracy and scientific relevance of pathology data acquired during a medical device or combination drug-device implantation study.


Food and Chemical Toxicology 176 (2023) 113734



Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: [www.elsevier.com/locate/foodchemtox](http://www.elsevier.com/locate/foodchemtox)



### Chronic toxicity and carcinogenicity study of dietary gardenia blue in Sprague Dawley rats

Robert Maronpot<sup>a</sup>, Yuval Ramot<sup>b,c</sup>, Abraham Nyska<sup>d,e</sup>, Christopher Sproul<sup>e</sup>, Rebecca Moore<sup>e</sup>,  
Mihoko Koyanagi<sup>f</sup>, Shuichi Chiba<sup>f</sup>, Masayuki Nishino<sup>f</sup>, Shim-mo Hayashi<sup>g,h</sup>

<sup>a</sup> Maronpot Consulting, LLC, 1612 Medfield Road, Raleigh, NC, 27607, USA

<sup>b</sup> Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

<sup>c</sup> Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel

<sup>d</sup> Toxicologic Pathology, Tel Aviv and Tel Aviv University, Israel

<sup>e</sup> Integrated Laboratory Systems, LLC, 601 Keystone Park Drive, Morrisville, NC, 27560, USA

<sup>f</sup> Global Scientific and Regulatory Affairs, San-Ei Gen F.F.I., Inc., 1-1-11 Sanwa-cho, Toyonaka, Osaka, 561-8588, Japan

<sup>g</sup> National Institute of Health Sciences, Kawasaki, Kanagawa, Japan

<sup>h</sup> Laboratory of Veterinary Pathology, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan

#### ARTICLE INFO

Handling Editor: Dr. Bryan Delaney

#### Keywords:

Toxicity  
Gardenia blue  
Carcinogenicity  
Rats

#### ABSTRACT

In this combined chronic toxicity/carcinogenicity study of gardenia blue as a natural food color additive, Sprague Dawley rats were administered 0.5%, 2.5%, or 5.0% gardenia blue via the feed or carrier diet (0.0% gardenia blue) for 12 (chronic toxicity cohort) or 24 (carcinogenicity cohort) months. No abnormal clinical, ophthalmological, neurotoxicity or clinical pathology changes were attributed to treatment, and there was no increase in mortality due to gardenia blue exposure. The only treatment-related change was grossly observed blue discoloration of the stomach, intestines, and mesenteric lymph nodes as well as reversible dark discoloration of the kidneys all without associated histopathology. The no-observed-adverse-effect level (NOAEL) for gardenia blue exposure via the diet for one or two years was determined to be 5.0% (2175.3 mg/kg body weight/day in male rats and 3075.4 mg/kg body weight/day in female rats).



ELSEVIER



# Oral chronic toxicity and carcinogenicity study of *alpha*-glycosyl isoquercitrin (AGIQ) in Sprague Dawley rats

[Robert Maronpot](#)<sup>a</sup> [✉](#), [Yuval Ramot](#)<sup>b c</sup>, [Abraham Nyska](#)<sup>d</sup>, [Christopher Sproul](#)<sup>e</sup>, [Rebecca Moore](#)<sup>e</sup>, [Brad Bolon](#)<sup>f</sup>, [Shim-mo Hayashi](#)<sup>g</sup>

[Show more](#) [∨](#)

[Int J Toxicol.](#) 2023 Jan 12;10915818231152613. doi: 10.1177/10915818231152613.

Online ahead of print.

## Preclinical In-Vivo Safety of a Novel Thyrotropin-Releasing Hormone-Loaded Biodegradable Nanoparticles After Intranasal Administration in Rats and Primates

[Yuval Ramot](#)<sup>1 2</sup>, [Yakir Rottenberg](#)<sup>1 3</sup>, [Abraham J Domb](#)<sup>4</sup>, [Michael J Kubek](#)<sup>5</sup>, [Kevin D Williams](#)<sup>6</sup>, [Abraham Nyska](#)<sup>7</sup>

[J Toxicol Pathol.](#) 2023 Jan;36(1):11-19. doi: 10.1293/tox.2022-0079. Epub 2022 Oct 31.

## Safety and efficacy of a novel robotic, fractional micro-coring device in a swine model

[Yuval Ramot](#)<sup>1 2</sup>, [Udi Vazana](#)<sup>3</sup>, [Orna Cacical](#)<sup>3</sup>, [Abraham Nyska](#)<sup>4 5</sup>

Affiliations [+](#) expand

PMID: 36683728 PMCID: [PMC9837470](#) DOI: [10.1293/tox.2022-0079](#)

[Free PMC article](#)

Original Article

## Treatment of contaminated radial fracture in Sprague-Dawley rats by application of a degradable polymer releasing gentamicin

Yuval Ramot<sup>1†</sup>, Michal Steiner<sup>2†</sup>, Netanel Amouyal<sup>2</sup>, Yossi Lavie<sup>2</sup>, Guy Klaiman<sup>2</sup>, Abraham J. Domb<sup>3</sup>, Abraham Nyska<sup>4\*</sup>, and Tal Hagigit<sup>5</sup>

<sup>1</sup> Faculty of Medicine, The Hebrew University of Jerusalem, Israel; The Department of Dermatology, Hadassah Medical Center, POB 12000, Jerusalem, 9112001, Israel

<sup>2</sup> Envigo CRS (Israel), Einstein Street, 13B, P.O.B 4019, Science Park, Ness Ziona, Israel

<sup>3</sup> Institute of Drug Research, School of Pharmacy-Faculty of Medicine, The Hebrew University of Jerusalem, POB 12000, Jerusalem, 9112001 Israel

<sup>4</sup> Consultant in Toxicologic Pathology, Tel Aviv and Tel Aviv University, Yehuda HaMaccabi 31, Tel Aviv, 6200515, Israel

<sup>5</sup> Dexcel Pharma Technologies Ltd., 1 Dexcel St., Or-Akiva, 3060000, Israel

*J Toxicol Pathol* 2021; 34: 181–211

Review

## The toxicologic pathology aspects of selected natural herbal products and related compounds

Ruba Ibrahim<sup>1, 2</sup>, Abraham Nyska<sup>3, 4\*</sup>, June Dunnick<sup>5</sup>, and Yuval Ramot<sup>1, 2</sup>

<sup>1</sup> Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

<sup>2</sup> Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel

<sup>3</sup> Consultant in Toxicologic Pathology, Yehuda HaMaccabi 31, floor 5, Tel Aviv 6200515, Israel

<sup>4</sup> Tel Aviv University, Tel Aviv, Israel

<sup>5</sup> Toxicology Branch, Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

Special issue: Review

polymers  
advanced  
technologies


Received: 18 September 2013, Revised: 30 October 2013, Accepted: 10 November 2013, Published online in Wiley Online Library: 7 January 2014


(wileyonlinelibrary.com) DOI: 10.1002/pat.3238

## Histopathology of biodegradable polymers: challenges in interpretation and the use of a novel compact MRI for biocompatibility evaluation<sup>†</sup>

Abraham Nyska<sup>a\*</sup>, Yael S. Schiffenbauer<sup>b</sup>, Catherine T. Brami<sup>b</sup>, Robert R. Maronpot<sup>c</sup> and Yuval Ramot<sup>d</sup>

# Local Tolerability and Performance Evaluation in Domestic Pigs of a Fractional Radiofrequency Device for Dermatologic Treatment

Toxicologic Pathology  
1-8  
© The Author(s) 2020  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/0192623320922958  
journals.sagepub.com/home/tpx  


Yuval Ramot<sup>1</sup> , Guy Klaiman<sup>2</sup>, Michal Steiner<sup>2</sup>, Yossi Lavie<sup>2</sup>,  
Inna Belenky<sup>3</sup>, and Abraham Nyska<sup>4</sup>

Food and Chemical Toxicology 97 (2016) 354–366



Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: [www.elsevier.com/locate/foodchemtox](http://www.elsevier.com/locate/foodchemtox)



Ninety-day toxicity and single-dose toxicokinetics study of *alpha*-glycosyl isoquercitrin in Sprague-Dawley rats



Abraham Nyska<sup>a,\*</sup>, Shim-mo Hayashi<sup>b</sup>, Mihoko Koyanagi<sup>b</sup>, Jeffrey P. Davis<sup>c</sup>,  
Micheal P. Jokinen<sup>c</sup>, Yuval Ramot<sup>d</sup>, Robert R. Maronpot<sup>e</sup>

<sup>a</sup> Sackler School of Medicine, Tel Aviv University, Toxicologic Pathology, Timrat, Israel


<sup>b</sup> Global Scientific and Regulatory Affairs, San-Ei Gen, FFL, Inc., Osaka, Japan


<sup>c</sup> Integrated Laboratory Systems, Research Triangle Park, NC, USA

<sup>d</sup> Hadassah - Hebrew University Medical Center, Jerusalem, Israel

<sup>e</sup> Maronpot Consulting LLC, Raleigh, NC, USA

# Local Tolerance and Biodegradability of a Novel Biodegradable Artificial Dura Mater Graft Following Implantation Onto a Dural Defect in Rabbits

Toxicologic Pathology  
1-9  
© The Author(s) 2020  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/0192623320947075  
journals.sagepub.com/home/tpx  


Yuval Ramot<sup>1</sup> , Sagi Harnof<sup>2</sup>, Ido Klein<sup>3</sup>, Netanel Amouyal<sup>3</sup>,  
Michal Steiner<sup>3</sup>, Nora Nseir Manassa<sup>4</sup>, Amir Bahar<sup>4</sup>,  
Serge Rousselle<sup>5</sup>, and Abraham Nyska<sup>6</sup>

## Chemical-Induced Oral Squamous Cell Neoplasms in Rodents: An Overview of NTP 2-Year Cancer Studies

Ruba Ibrahim<sup>1,2</sup>, Amy Brix<sup>3</sup>, David E. Malarkey<sup>4</sup>, Abraham Nyska<sup>5</sup>, Michal Asif<sup>1,2</sup>, and Yuval Ramot<sup>1,2</sup>

Toxicologic Pathology  
1-15  
© The Author(s) 2021  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/0192623321989956  
journals.sagepub.com/home/tpx  
SAGE

## Microscope-Based Automated Quantification of Liver Fibrosis in Mice Using a Deep Learning Algorithm

Yuval Ramot<sup>1,2</sup>, Ameya Deshpande<sup>3</sup>, Virginia Morello<sup>4</sup>, Paolo Michieli<sup>4,5</sup>, Tehila Shlomov<sup>1,6</sup>, and Abraham Nyska<sup>7</sup>

Toxicologic Pathology  
1-8  
© The Author(s) 2021  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/01926233211003866  
journals.sagepub.com/home/tpx  
SAGE

### BASIC INVESTIGATION

OPEN

## CorNeat KPro: Ocular Implantation Study in Rabbits

Gilad Litvin, MD,\* Ido Klein, BSc, MBA,\* Yoav Litvin, PhD,† Guy Klaiman, PhD,‡ and Abraham Nyska, DVM§

*J Toxicol Pathol* 2021; 34: \*\*-\*\*

Original Article

## Safety and efficacy of sFilm-FS, a novel biodegradable fibrin sealant, in Göttingen minipigs

Yuval Ramot<sup>1,2</sup>, Michal Steiner<sup>3</sup>, Yossi Lavie<sup>3</sup>, Nati Ezov<sup>3</sup>, Orgad Laub<sup>4</sup>, Eran Cohen<sup>4</sup>, Yotam Schwartz<sup>4</sup>, and Abraham Nyska<sup>5,6</sup>\*

<sup>1</sup> Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

<sup>2</sup> Department of Dermatology, Hadassah Medical Center, Jerusalem, 91120, Israel

<sup>3</sup> Envigo CRS (Israel), Ness Ziona, 7403617, Israel

<sup>4</sup> Sealantium Medical, Afek Industrial Area, P.O.B. 11817, Rosh Ha'Ayin, 4809239, Israel

<sup>5</sup> Consultant in Toxicologic Pathology, Yehuda HaMaccabi 31, floor 5, Tel Aviv, 6200515, Israel

<sup>6</sup> Tel Aviv University, 6200515, Israel

## Toxicity and Local Tolerance of COVID-eVax, a Plasmid DNA Vaccine for SARS-CoV-2, Delivered by Electroporation

Toxicologic Pathology  
1-14  
© The Author(s) 2021  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/01926233211042263  
journals.sagepub.com/home/tpx  
SAGE

Yuval Ramot<sup>1,2</sup>, Gianfranco Caselli<sup>3</sup>, Luigi Aurisicchio<sup>4,5</sup>, Isabella Andreini<sup>6</sup>, Emanuele Marra<sup>4</sup>, Laura Luberto<sup>4</sup>, Daniela Stoppoloni<sup>4</sup>, Maria Lucrezia Pacello<sup>4</sup>, Laura Monetini<sup>7</sup>, and Abraham Nyska<sup>8</sup>

*Toxicologic Pathology*, 43: 1127-1140, 2015  
Copyright © 2015 by The Author(s)  
ISSN: 0192-6233 print / 1533-1601 online  
DOI: 10.1177/0192623315600275

## Long-term Local and Systemic Safety of Poly(L-lactide-co-epsilon-caprolactone) after Subcutaneous and Intra-articular Implantation in Rats

YUVAL RAMOT<sup>1</sup>, ABRAHAM NYSKA<sup>2</sup>, ELANA MARKOVITZ<sup>3</sup>, ASSAF DEKEL<sup>3</sup>, GUY KLAIMAN<sup>4</sup>, MORAN HAIM ZADA<sup>5</sup>, ABRAHAM J. DOMB<sup>5</sup>, AND ROBERT R. MARONPOT<sup>6</sup>

<sup>1</sup>Hadassah—Hebrew University Medical Center, Jerusalem, Israel

<sup>2</sup>Tel Aviv University and Consultant in Toxicologic Pathology, Timrat, Israel

<sup>3</sup>Ortho-Space Ltd., Caesarea, Israel

<sup>4</sup>Harlan Biotech Israel Ltd., Rehovot, Israel

<sup>5</sup>Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel

<sup>6</sup>Maronpot Consulting LLC, Raleigh, North Carolina, USA

## Biocompatibility and Systemic Safety of a Novel Implantable Annuloplasty Ring for the Treatment of Mitral Regurgitation in a Minipig Model

Toxicologic Pathology  
1-8  
© The Author(s) 2016  
Reprints and permission:  
sagepub.com/journalsPermissions.nav  
DOI: 10.1177/0192623315627217  
tpx.sagepub.com  
SAGE

Yuval Ramot<sup>1</sup>, Serge D. Rousselle<sup>2</sup>, Nadav Yellin<sup>3</sup>, Udi Willenz<sup>4</sup>, Itai Sabag<sup>4</sup>, Avi Avner<sup>5</sup>, and Abraham Nyska<sup>6</sup>

This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

ACS APPLIED  
BIO MATERIALS

www.acsabm.org



Article




## Biodegradable Breast Tissue Marker Clip

Moran Haim Zada, Zehava Gallimidi, Michal Schlesinger—Laufer, Abraham Nyska, and Abraham J. Domb\*



Article

# Design and Evaluation of Dissolvable Microneedles for Treating Atopic Dermatitis

Noa Ben David <sup>1</sup>, Yuval Richtman <sup>1</sup>, Adi Gross <sup>1</sup>, Ruba Ibrahim <sup>2,3</sup>, Abraham Nyska <sup>4</sup>, Yuval Ramot <sup>2,3,\*</sup>  
and Boaz Mizrahi <sup>1,\*</sup>

<sup>1</sup> Faculty of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel

<sup>2</sup> Department of Dermatology, Hadassah Medical Center, Jerusalem 9112001, Israel

<sup>3</sup> Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel

<sup>4</sup> Sackler School of Medicine, Tel Aviv University, Tel Aviv 6200515, Israel

\* Correspondence: yramot@gmail.com (Y.R.); bmizrahi@technion.ac.il (B.M.)

*J Toxicol Pathol* 2023; 36: 11–19

Original Article

## Safety and efficacy of a novel robotic, fractional micro-coring device in a swine model

Yuval Ramot<sup>1,2</sup>, Udi Vazana<sup>3</sup>, Orna Cacical<sup>3</sup>, and Abraham Nyska<sup>4,5\*</sup>

<sup>1</sup> Faculty of Medicine, Hebrew University of Jerusalem, Campus Ein Kerem, Jerusalem 9112102, Israel

<sup>2</sup> Department of Dermatology, Hadassah Medical Center, Campus Ein Kerem, Jerusalem 9112102, Israel

<sup>3</sup> LAHAV CRO, Kibbutz Lahav, Israel

<sup>4</sup> Consultant in Toxicologic Pathology, Yehuda HaMaccabi 31, Tel Aviv 6200515, Israel

<sup>5</sup> Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel